CD8A and neoplasm: In a study, the feasibility, safety, and immunogenicity of a vaccine targeting up to 20 predicted personalized tumor neoantigens were demonstrated, and the vaccine-induced multifunctional CD4+ and CD8+ T cells targeted 60% (58) and 16% (15) of the 97 unique neoantigens, respectively [271].